{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:48:05Z","timestamp":1782107285534,"version":"3.54.5"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Caris Life Sciences"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate-specific membrane antigen (PSMA; FOLH1) is a cell-surface target for diagnostics and treatment in prostate cancer. We utilized a database of molecularly-profiled prostate tumors to evaluate clinical, genomic, and immunologic correlates of high FOLH1 RNA expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Prostate cancer specimens (N\u2009=\u20097,082) underwent DNA\/RNA sequencing and immunohistochemistry at Caris Life Sciences. FOLH1-High\/Low expression was defined by upper\/lower quartiles or median transcripts per million. Overall survival (OS) was calculated from insurance claims.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Prostate adenocarcinoma had 2.97-fold higher FOLH1 expression compared to high-grade neuroendocrine prostate cancer (q\u2009&amp;lt;\u20090.0001). Of 7,020 adenocarcinomas, 4,464 were primary prostate samples, 828 were lymph node metastases, and 1,686 were distant metastases. FOLH1 expression varied across metastatic sites (highest in lymph node and lowest in liver; 1.2-fold difference, q\u2009&amp;lt;\u20090.05). FOLH1-High tumors were enriched in AR-V7 variants (10.1% vs 4.5%, q\u2009&amp;lt;\u20090.05) and associated with higher androgen receptor (AR) signaling (0.82 vs 0.78, q\u2009&amp;lt;\u20090.05). Conversely, FOLH1-Low tumors were enriched with FOXA1 (12.2% vs 6.4%), APC (11.4% vs 3.0%), PIK3CA (5.8% vs 2.7%), and PIK3R1 (2.6% vs 0.48%) mutations (q\u2009&amp;lt;\u20090.05). FOLH1-High tumors had a lower M1:M2 ratio, fewer Tregs and CD8+ T cells, higher immune checkpoint expression, and lower interferon signature scores. FOLH1-High primary tumors were more frequently microsatellite instability-High, tumor mutational burden-High, and PD-L1-positive. Among patients with metastatic tumors, median OS was improved in the FOLH1-High group (31.9 vs 23.3\u2009months, P\u2009&amp;lt;\u2009.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This enhanced understanding of the distinct molecular and clinical profiles of FOLH1-expressing prostate cancers may inform optimization of PSMA-directed treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf338","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T18:17:48Z","timestamp":1759861068000},"source":"Crossref","is-referenced-by-count":2,"title":["Molecular and clinical correlates of high\n                    <i>FOLH1<\/i>\n                    (PSMA) RNA expression in primary and metastatic prostate cancer"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-7963","authenticated-orcid":false,"given":"Rana R","family":"McKay","sequence":"first","affiliation":[{"name":"Department of Medicine and Urology, University of California San Diego , La Jolla, CA 92037,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan S","family":"Nazari","sequence":"additional","affiliation":[{"name":"Medical Affairs, Caris Life Sciences , Phoenix, AZ 85040,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-8031","authenticated-orcid":false,"given":"Andrew","family":"Elliott","sequence":"additional","affiliation":[{"name":"Medical Affairs, Caris Life Sciences , Phoenix, AZ 85040,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1685-8568","authenticated-orcid":false,"given":"Jennifer R","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Medical Affairs, Caris Life Sciences , Phoenix, AZ 85040,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent S","family":"Rose","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine and Applied Sciences, University of California, San Diego , San Diego, CA 92093,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro C","family":"Barata","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, University Hospitals Seidman Cancer Center , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kilari","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Division of Hematology and Oncology , Milwaukee, WI 53226,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Garje","sequence":"additional","affiliation":[{"name":"Genitourinary Medical Oncology, Miami Cancer Institute, Baptist Health South Florida , Miami, FL 33176,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-0428","authenticated-orcid":false,"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Huntsman Cancer Institute (NCI-CCC), University of Utah , Salt Lake City, UT 84112,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norm","family":"Smith","sequence":"additional","affiliation":[{"name":"Medical Affairs, Caris Life Sciences , Phoenix, AZ 85040,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S","family":"Antonarakis","sequence":"additional","affiliation":[{"name":"Department of Medicine, Masonic Cancer Center, University of Minnesota , Minneapolis, MN 55455,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bagrodia","sequence":"additional","affiliation":[{"name":"Department of Medicine and Urology, University of California San Diego , La Jolla, CA 92037,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3259-2226","authenticated-orcid":false,"given":"Himisha","family":"Beltran","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA 02215,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"2025111120321587900_oyaf338-B1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA"},{"key":"2025111120321587900_oyaf338-B2","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res"},{"key":"2025111120321587900_oyaf338-B3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","article-title":"Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues","volume":"1","author":"Wright","year":"1995","journal-title":"Urol Oncol"},{"key":"2025111120321587900_oyaf338-B4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","article-title":"Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases","volume":"52","author":"Sweat","year":"1998","journal-title":"Urology"},{"key":"2025111120321587900_oyaf338-B5","doi-asserted-by":"crossref","first-page":"17588359231182293","DOI":"10.1177\/17588359231182293","article-title":"The current status of prostate cancer treatment and PSMA theranostics","volume":"15","author":"Uemura","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"2025111120321587900_oyaf338-B6","first-page":"S13","article-title":"Overview of prostate-specific membrane antigen","volume":"6 Suppl 10","author":"Chang","year":"2004","journal-title":"Rev Urol"},{"key":"2025111120321587900_oyaf338-B7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","article-title":"Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer","volume":"76","author":"Paschalis","year":"2019","journal-title":"Eur Urol"},{"key":"2025111120321587900_oyaf338-B8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.eururo.2024.09.005","article-title":"Molecular hallmarks of prostate-specific membrane antigen in treatment-na\u00efve prostate cancer","volume":"86","author":"Weiner","year":"2024","journal-title":"Eur Urol"},{"key":"2025111120321587900_oyaf338-B9","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"key":"2025111120321587900_oyaf338-B10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"2025111120321587900_oyaf338-B11","doi-asserted-by":"crossref","first-page":"462","DOI":"10.23736\/S0393-2249.18.03081-3","article-title":"The role of 68Ga-PSMA PET\/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature","volume":"70","author":"Eissa","year":"2018","journal-title":"Minerva Urol Nefrol"},{"key":"2025111120321587900_oyaf338-B12","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"2025111120321587900_oyaf338-B13","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients","volume":"44","author":"Afshar-Oromieh","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025111120321587900_oyaf338-B14","doi-asserted-by":"crossref","first-page":"1355236","DOI":"10.3389\/fmed.2024.1355236","article-title":"Effect of (18)F-DCFPyL PET on changes in management of patients with prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Wang","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2025111120321587900_oyaf338-B15","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1080\/14656566.2024.2385726","article-title":"PSMA-based therapeutics for prostate cancer","volume":"25","author":"Stamatakos","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"2025111120321587900_oyaf338-B16","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"2025111120321587900_oyaf338-B17","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: Lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025111120321587900_oyaf338-B18","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1200\/JCO.2023.41.16_suppl.5028","article-title":"Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results","volume":"41","author":"Herrmann","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025111120321587900_oyaf338-B19","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025111120321587900_oyaf338-B20","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025111120321587900_oyaf338-B21","doi-asserted-by":"crossref","first-page":"e1480","DOI":"10.1093\/oncolo\/oyae168","article-title":"Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors","volume":"29","author":"Morgenstern-Kaplan","year":"2024","journal-title":"Oncologist"},{"key":"2025111120321587900_oyaf338-B22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2025111120321587900_oyaf338-B23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat Methods"},{"key":"2025111120321587900_oyaf338-B24","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"key":"2025111120321587900_oyaf338-B25","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"2025111120321587900_oyaf338-B26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med"},{"key":"2025111120321587900_oyaf338-B27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.exphem.2020.01.002","article-title":"ASXL1 mutation in clonal hematopoiesis","volume":"83","author":"Fujino","year":"2020","journal-title":"Exp Hematol"},{"key":"2025111120321587900_oyaf338-B28","doi-asserted-by":"crossref","first-page":"e2300132","DOI":"10.1200\/PO.23.00132","article-title":"Clonal hematopoiesis: updates and implications at the solid tumor-immune interface","volume":"7","author":"Buttigieg","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"2025111120321587900_oyaf338-B29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","article-title":"N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer","volume":"30","author":"Dardenne","year":"2016","journal-title":"Cancer Cell"},{"key":"2025111120321587900_oyaf338-B30","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"2025111120321587900_oyaf338-B31","doi-asserted-by":"crossref","first-page":"R187","DOI":"10.1530\/ERC-12-0085","article-title":"The reactive stroma microenvironment and prostate cancer progression","volume":"19","author":"Barron","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"2025111120321587900_oyaf338-B32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1126\/science.aay0267","article-title":"Regenerative potential of prostate luminal cells revealed by single-cell analysis","volume":"368","author":"Karthaus","year":"2020","journal-title":"Science"},{"key":"2025111120321587900_oyaf338-B33","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/ERC-18-0226","article-title":"Neuroendocrine differentiation of prostate cancer leads to PSMA suppression","volume":"26","author":"Bakht","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"2025111120321587900_oyaf338-B34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht","year":"2025","journal-title":"Nat Rev Urol"},{"key":"2025111120321587900_oyaf338-B35","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/modpathol.2014.77","article-title":"Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer","volume":"28","author":"Queisser","year":"2015","journal-title":"Mod Pathol"},{"key":"2025111120321587900_oyaf338-B36","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.162907","article-title":"Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer","volume":"8","author":"Sayar","year":"2023","journal-title":"JCI Insight"},{"key":"2025111120321587900_oyaf338-B37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrurol.2017.144","article-title":"WNT signalling in prostate cancer","volume":"14","author":"Murillo-Garz\u00f3n","year":"2017","journal-title":"Nat Rev Urol"},{"key":"2025111120321587900_oyaf338-B38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124507","article-title":"The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling","volume":"21","author":"Shorning","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025111120321587900_oyaf338-B39","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/pros.22910","article-title":"Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer","volume":"75","author":"Murga","year":"2015","journal-title":"Prostate"},{"key":"2025111120321587900_oyaf338-B40","doi-asserted-by":"crossref","first-page":"486798","DOI":"10.1155\/2014\/486798","article-title":"The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy","volume":"2014","author":"Lanciotti","year":"2014","journal-title":"Biomed Res Int"},{"key":"2025111120321587900_oyaf338-B41","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"2025111120321587900_oyaf338-B42","doi-asserted-by":"crossref","first-page":"TPS352","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS352","article-title":"A randomized phase I\/II study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with or without ipilimumab in patients with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI trial)","volume":"42","author":"Krafft","year":"2024","journal-title":"JCO"},{"key":"2025111120321587900_oyaf338-B43","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1200\/JCO.2025.43.16_suppl.5016","article-title":"177Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): an investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001)","volume":"43","author":"Sandhu","year":"2025","journal-title":"JCO"},{"key":"2025111120321587900_oyaf338-B44","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13030734","article-title":"Prostate cancer liver metastasis: an ominous metastatic site in need of distinct management strategies","volume":"13","author":"Shiner","year":"2024","journal-title":"J Clin Med"},{"key":"2025111120321587900_oyaf338-B45","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.2024.42.4_suppl.208","article-title":"Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results","volume":"42","author":"Herrmann","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025111120321587900_oyaf338-B46","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2967\/jnumed.118.223099","article-title":"Rapid modulation of PSMA expression by androgen deprivation: serial (68)Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade","volume":"60","author":"Emmett","year":"2019","journal-title":"J Nucl Med"},{"key":"2025111120321587900_oyaf338-B47","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025111120321587900_oyaf338-B48","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"2025111120321587900_oyaf338-B49","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1038\/s41388-020-01479-6","article-title":"Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors","volume":"39","author":"Zhu","year":"2020","journal-title":"Oncogene"},{"key":"2025111120321587900_oyaf338-B50","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168649","article-title":"Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs","volume":"134","author":"Han","year":"2024","journal-title":"J Clin Invest"},{"key":"2025111120321587900_oyaf338-B51","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","article-title":"Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy","volume":"48","author":"Wright","year":"1996","journal-title":"Urology"},{"key":"2025111120321587900_oyaf338-B52","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","article-title":"Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer","volume":"4","author":"Bakht","year":"2023","journal-title":"Nat Cancer"},{"key":"2025111120321587900_oyaf338-B53","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.eururo.2018.01.006","article-title":"Efficacy, predictive factors, and prediction nomograms for 68Ga-labeled prostate-specific membrane antigen\u2013ligand positron-emission tomography\/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy","volume":"73","author":"Rauscher","year":"2018","journal-title":"Eur Urol"},{"key":"2025111120321587900_oyaf338-B54","doi-asserted-by":"crossref","first-page":"24799","DOI":"10.1038\/srep24799","article-title":"Cross-tissue analysis of gene and protein expression in normal and cancer tissues","volume":"6","author":"Kosti","year":"2016","journal-title":"Sci Rep"},{"key":"2025111120321587900_oyaf338-B55","doi-asserted-by":"crossref","first-page":"17562872231182219","DOI":"10.1177\/17562872231182219","article-title":"Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer","volume":"15","author":"Zarrabi","year":"2023","journal-title":"Ther Adv Urol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf338\/64539594\/oyaf338.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf338\/64539594\/oyaf338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf338\/64539594\/oyaf338.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:32:27Z","timestamp":1762911147000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf338\/8277021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf338","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,7]]},"article-number":"oyaf338"}}